874 related articles for article (PubMed ID: 8803910)
1. The role of anti-malarials in rheumatoid arthritis--the American experience.
Khraishi MM; Singh G
Lupus; 1996 Jun; 5 Suppl 1():S41-4. PubMed ID: 8803910
[TBL] [Abstract][Full Text] [Related]
2. [Evidence-based treatment of methotrexate-resistant rheumatoid arthritis. Combinations of conventional disease-modifying antirheumatic agents].
Schnabel A; Gross WL
Dtsch Med Wochenschr; 2003 Jan; 128(4):147-9. PubMed ID: 12589584
[No Abstract] [Full Text] [Related]
3. [Combination therapy of rheumatoid arthritis].
Hansen A; Jensen T
Ugeskr Laeger; 1998 Sep; 160(40):5772-6. PubMed ID: 9782754
[TBL] [Abstract][Full Text] [Related]
4. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
[TBL] [Abstract][Full Text] [Related]
5. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.
Puolakka K; Kautiainen H; Möttönen T; Hannonen P; Korpela M; Julkunen H; Luukkainen R; Vuori K; Paimela L; Blåfield H; Hakala M; Leirisalo-Repo M
Arthritis Rheum; 2004 Jan; 50(1):55-62. PubMed ID: 14730599
[TBL] [Abstract][Full Text] [Related]
6. DMARDs in the treatment of rheumatoid arthritis: current agents and future developments.
Simon LS
Int J Clin Pract; 2000 May; 54(4):243-9. PubMed ID: 10912314
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.
Hurst S; Kallan MJ; Wolfe FJ; Fries JF; Albert DA
J Rheumatol; 2002 Aug; 29(8):1639-45. PubMed ID: 12180722
[TBL] [Abstract][Full Text] [Related]
8. [The role of the conventional drugs in the treatment of rheumatoid arthritis].
Fantini F
Recenti Prog Med; 2003; 94(7-8):330-8. PubMed ID: 12868241
[TBL] [Abstract][Full Text] [Related]
9. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient.
Ranganath VK; Furst DE
Clin Geriatr Med; 2005 Aug; 21(3):649-69, viii. PubMed ID: 15911212
[TBL] [Abstract][Full Text] [Related]
10. How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trial.
Matteson EL; Weyand CM; Fulbright JW; Christianson TJ; McClelland RL; Goronzy JJ
Rheumatology (Oxford); 2004 May; 43(5):619-25. PubMed ID: 14983105
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacotherapy of patients with (early) rheumatoid arthritis].
Jacobs JW; Blaauw AA; Dijkmans BA; van Riel PL; Bijlsma JW
Ned Tijdschr Geneeskd; 2000 Jan; 144(5):211-6. PubMed ID: 10682647
[TBL] [Abstract][Full Text] [Related]
12. [Armentarium and strategies for the treatment of rheumatoid arthritis].
Lioté F
Rev Prat; 2005 Dec; 55(19):2146-60. PubMed ID: 16544925
[TBL] [Abstract][Full Text] [Related]
13. The use of antimalarials in combination with other disease modifying agents in rheumatoid arthritis--the French experience.
Kahan A; Menkès CJ
Lupus; 1996 Jun; 5 Suppl 1():S45-9. PubMed ID: 8803911
[TBL] [Abstract][Full Text] [Related]
14. Current concepts in clinical therapeutics: disease-modifying drugs for rheumatoid arthritis.
Pugh MC; Pugh CB
Clin Pharm; 1987 Jun; 6(6):475-91. PubMed ID: 3319362
[TBL] [Abstract][Full Text] [Related]
15. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis.
Singh G; Fries JF; Williams CA; Zatarain E; Spitz P; Bloch DA
J Rheumatol; 1991 Feb; 18(2):188-94. PubMed ID: 1673721
[TBL] [Abstract][Full Text] [Related]
16. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
Rantalaiho V; Korpela M; Hannonen P; Kautiainen H; Järvenpää S; Leirisalo-Repo M; Hakala M; Puolakka K; Julkunen H; Luosujärvi R; Möttönen T;
Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
[TBL] [Abstract][Full Text] [Related]
17. Drugs for rheumatoid arthritis.
Med Lett Drugs Ther; 2000 Jul; 42(1082):57-64. PubMed ID: 10887424
[No Abstract] [Full Text] [Related]
18. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis.
Schiff MH; Whelton A
Semin Arthritis Rheum; 2000 Dec; 30(3):196-208. PubMed ID: 11124283
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
Gubar' EE; Bochkova AG; Bunchuk NV
Ter Arkh; 2008; 80(5):25-30. PubMed ID: 18590110
[TBL] [Abstract][Full Text] [Related]
20. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
